source
- Sanofi halts Phase 3 trial of riliprubart in CIDP after interim analysis shows unlikely efficacySanofi announced Wednesday that it is stopping the Phase 3 MOBILIZE study of its experimental anti‑inflammatory drug riliprubart in patients with chronic inflammatory demyelinating polyneuropathy (…
- Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA reviewBeren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…